1.Methylation Profiling for the Prediction of Barrett’s Esophagus ProgressionKarsten Schulmann, Jing Yin, Anca Sterian, Theresa Xu, Fumiako Sato, Lamar Bryant, Yuriko Mori, Andreea Olaru, Elena Deacu, Suna Wang, Dean E. Brenner, Mark J. Krasna, John M. Abraham, John A. Baron, Bruce D. Greenwald, and Stephen J. Meltzer
2.Tegaserod Significantly Improves Esophageal Mechanical Pain Threshold, Regurgitation, and Global Preference Vs. Placebo in Patients With Functional HeartburnS. Rodriguez-Stanley, S. Zubaidi, M. Wolff, Susan Riley, H. Proskin, and P.B. Miner, Jr.
3.A Phase III, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Crohn’s Disease (ENACT-2)W. Sandborn, J.-F. Colombel, R. Enns, B. Feagan, S. Hanauer, I. Lawrance, R. Panaccione, M. Sanders, S. Schreiber, S. Targan, S. van Deventer, and P. Rutgeerts
4.A Randomized, Double-Blind, Placebo-Controlled Trial of the Human Anti-TNF-α Monoclonal Antibody Adalimumab for the Induction of Remission in Patients with Moderate to Severely Active Crohn’s DiseaseStephen Hanauer, Milan Lukáš, Donald MacIntosh, Paul Rutgeerts, William Sandborn, and Paul Pollack
5.Fontolizumab (Huzaf), a Humanized Anti-IFN-Gamma Antibody, Has Clinical Activity and Excellent Tolerability in Moderate to Severe Crohn’s DiseaseDaniel Hommes, Tatiana Mikhajlova, Simeon Stoinov, Davor Stimac, Boris Vucelic, Janos Lonovics, Maria Zakuciova, Geert D’Haens, Gert Van Assche, and Tillman Pearce
6.A Heightened Global Response of Interferon-Alfa Treatment on Host Gene Transcription Is Associated With Clearance of HCV After Interferon TherapyXiao-Song He, Xuhuai Ji, Ramsey Cheung, Lawrence M. Pfeffer, Robert Tibshirani, and Harry B. Greenberg
